Zentalis Pharmaceuticals, Llc Ret. on equity
What is the Ret. on equity of Zentalis Pharmaceuticals, Llc?
The Ret. on equity of Zentalis Pharmaceuticals, Llc is -44.23%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Zentalis Pharmaceuticals, Llc
What does Zentalis Pharmaceuticals, Llc do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Companies with ret. on equity similar to Zentalis Pharmaceuticals, Llc
- Hostelworld plc has Ret. on equity of -44.37%
- 4SC AG has Ret. on equity of -44.35%
- Old Holdco has Ret. on equity of -44.32%
- Trajectory Alpha Acquisition Co has Ret. on equity of -44.32%
- Zenova PLC has Ret. on equity of -44.32%
- Exterran Corp has Ret. on equity of -44.28%
- Zentalis Pharmaceuticals, Llc has Ret. on equity of -44.23%
- Avricore Health has Ret. on equity of -44.18%
- Olema Pharmaceuticals has Ret. on equity of -44.18%
- Montage Gold has Ret. on equity of -44.18%
- Parazero has Ret. on equity of -44.16%
- MyoKardia has Ret. on equity of -44.16%
- Huffington Capital has Ret. on equity of -44.15%